understanding and overcoming resistance to btk and bcl-2 inhibitors in cll
Published 1 year ago • 120 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
3:12
btk and bcl2 inhibitor resistance in cll: session highlights
-
3:11
overcoming resistance to btk inhibition in cll
-
2:25
outcomes & healthcare utilization cost of patients with cll refractory to btk and bcl-2 inhibitors
-
1:51
understanding and overcoming resistance mechanisms to novel agents used in cll
-
3:37
clonal evolution and resistance mechanisms to bcl-2 receptor inhibition
-
25:56
lecture: cusp overlap and commissural alignment in tavr
-
8:15
enitociclib, a cdk9 inhibitor, for chronic lymphocytic leukemia (cll) - dr. mazyar shadman ash 2022
-
34:10
chronic lymphocytic leukemia (cll)
-
1:19
outcomes of cll patients following treatment with a covalent btk and bcl2 inhibitor
-
1:24
sequencing of btk inhibitors in cll
-
1:25
the current approach to managing patients with prefibrotic pmf
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
2:34
bruin study update: analysis of the mechanisms of resistance to pirtobrutinib in cll
-
1:58
comparing the safety & efficacy of reversible and irreversible btk inhibitors in cll
-
1:20
mechanisms of resistance to targeted therapies in cll
-
2:37
resistance to acalabrutinib in cll is mediated by btk mutations
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
1:10
next-generation btk inhibitors and their role in the cll treatment landscape
-
2:20
genomic evolution and resistance to pirtobrutinib in cll: insights from the bruin study
-
2:59
the future of cll treatment: more selective and reversible btk inhibitors
-
1:05
btk degraders in the treatment of cll
-
3:35
the current role of continuous btk inhibitors in cll treatment: benefits and drawbacks